Abcam Limited Overview
Pro stress-test →Abcam Limited is a life science company that focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company operates as a subsidiary of Danaher Corporation as of December 6, 2023. Abcam operates worldwide from 13 locations with 1,800 employees, of which 400 work in Research and Development.
Strategic Profile
Pro stress-test →The company's principal products include primary and secondary antibodies, conjugated antibodies and conjugation kits, singleplex immunoassays, proteins and peptides including cytokines, edited cell lines and lysates, and various other products including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. In April 2026, Abcam announced SimpleStep Ignite™ ELISA, a next generation chemiluminescent immunoassay platform.
Competitive Landscape
Pro stress-test →Abcam competes in the life science research tools and antibodies market against specialized reagent suppliers and larger diversified life sciences companies. Key competitors include providers of antibodies, assays, and protein research tools serving academic, pharmaceutical, and biotechnology customers. As a Danaher subsidiary, Abcam benefits from complementary product integration and cross-selling opportunities within Danaher's life sciences and diagnostics portfolio.
Industry Context
Abcam Limited operates in Life science research reagents and antibodies.
Key facts
Founded: 1998 · Headquarters: Cambridge, United Kingdom · Employees: 1,888 (as of April 2026) · Revenue: £361.7 million (2022); post-acquisition 2023-2026 financials not separately disclosed as Danaher subsidiary · Market cap: N/A